BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamat N, Kedia S, Ghoshal UC, Nehra A, Makharia G, Sood A, Midha V, Gupta V, Choudhuri G, Ahuja V. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study. Indian J Gastroenterol. 2019;38:44-54. [PMID: 30645725 DOI: 10.1007/s12664-018-0922-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Ghoshal UC, Rai S, Kulkarni A, Gupta A. Prediction of outcome of treatment of acute severe ulcerative colitis using principal component analysis and artificial intelligence. JGH Open. 2020;4:889-897. [PMID: 33102760 DOI: 10.1002/jgh3.12342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Tursi A. Performances of anti-TNFα antibodies as long-term maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:e1107-8. [PMID: 35048684 DOI: 10.1097/MEG.0000000000002220] [Reference Citation Analysis]
3 Chandra A, Kanth R, Thareja S. Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up. Biologics 2019;13:191-200. [PMID: 31819364 DOI: 10.2147/BTT.S214518] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Masnadi Shirazi K, Sotoudeh S, Masnadi Shirazi A, Moaddab SY, Nourpanah Z, Nikniaz Z. Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis: A randomized, double-blind controlled clinical trial. Clin Res Hepatol Gastroenterol 2021;45:101532. [PMID: 33067169 DOI: 10.1016/j.clinre.2020.08.010] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Rev Clin Immunol 2020;16:1019-28. [PMID: 32954893 DOI: 10.1080/1744666X.2021.1826311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Tapete G, Bertani L, Pieraccini A, Lynch EN, Giannotta M, Morganti R, Biviano I, Naldini S, Mumolo MG, De Nigris F, Calella F, Bagnoli S, Minciotti M, Maltinti S, Rentini S, Ceccarelli L, Lionetti P, Milla M, Costa F. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. Inflamm Bowel Dis 2021:izab027. [PMID: 33570142 DOI: 10.1093/ibd/izab027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhou HY, Guo B, Lufumpa E, Li XM, Chen LH, Meng X, Li BZ. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Immunol Invest 2021;50:323-37. [PMID: 32009472 DOI: 10.1080/08820139.2020.1714650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sahu P, Vuyyuru SK, Kante B, Agarwal A, Sharma R, Das P, Panwar R, Jain S, Bopanna S, Makharia G, Kedia S, Ahuja V. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. Indian J Gastroenterol 2020;39:388-97. [PMID: 32880844 DOI: 10.1007/s12664-020-01043-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Rajbhandari R, Blakemore S, Gupta N, Adler AJ, Noble CA, Mannan S, Nikolli K, Yih A, Joshi S, Bukhman G. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol 2020; 26(43): 6891-6908 [PMID: 33268969 DOI: 10.3748/wjg.v26.i43.6891] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Patil SA, Bhat S, Limdi JK, Farraye FA, Cross RK. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac048. [PMID: 35353189 DOI: 10.1093/ibd/izac048] [Reference Citation Analysis]
11 Kedia S, Mouli VP, Kamat N, Sankar J, Ananthakrishnan A, Makharia G, Ahuja V. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2020;115:340-9. [DOI: 10.14309/ajg.0000000000000527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
12 Wei S, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJQ, Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Review of Gastroenterology & Hepatology 2021;15:275-89. [DOI: 10.1080/17474124.2021.1840976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Talathi S, Baig KRKK. Biosimilars in inflammatory bowel disease. J Dig Dis 2020;21:610-20. [PMID: 32920972 DOI: 10.1111/1751-2980.12940] [Reference Citation Analysis]
14 Kumar P, Vuyyuru SK, Kante B, Sahu P, Goyal S, Madhu D, Jain S, Ranjan MK, Mundhra S, Golla R, Singh M, Virmani S, Gupta A, Yadav N, Kalaivani M, Sharma R, Das P, Makharia G, Kedia S, Ahuja V. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Aliment Pharmacol Ther 2022;55:1431-40. [PMID: 35229906 DOI: 10.1111/apt.16839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Barberio B, Cingolani L, Canova C, Barbieri G, Sablich R, Urbano MT, Bertani L, Costa F, Bodini G, Demarzo MG, Ferronato A, Buda A, Melatti P, Massimi D, Savarino EV, Zingone F. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Therap Adv Gastroenterol 2021;14:17562848211031420. [PMID: 34349836 DOI: 10.1177/17562848211031420] [Reference Citation Analysis]